Celiac disease (CD) is a vastly underdiagnosed malady due to its extremely variable clinical presentation. The diagnosis of CD requires invasive measures including serological testing of specific antibodies and jejunal biopsy. A noninvasive test helps increase the detection rate of this hitherto all too often unrecognized disease.

Fecal anti-transglutimase concentrations in untreated CD patients are significantly higher than in treated celiac disease patients and non CD subjects and may therefore be suited to detect active CD. In addition, ftTGA concentrations may be useful to monitor the adherence of CD patients to a gluten-free diet.

For futher information see:

FECAL TISSUE TRANSGLUTAMINASE ANTIBODY (FTTGA) CONCENTRATIONS CORRECTLY IDENTIFY PATIENTS WITH CELIAC DISEASE.